GLP-1 Drugs Could Change Global Health — But Only If the World Can Afford Them

Why this matters: A class of drugs already reshaping how wealthy countries treat obesity and diabetes is now being talked about as a potential turning point in HIV care. And if you’re not paying attention, you’re about to miss one of the biggest health stories of the decade.

At CROI 2026, researchers dropped findings that should be front-page news everywhere. GLP-1 receptor agonists — the same family of drugs as Ozempic and Wegovy — could be a genuine game-changer for people living with HIV, according to new data presented at the conference. But there’s a catch. A big one. These drugs are expensive, supply is tight, and the people who need them most can least afford them.

Let’s back up for a second.

What Are GLP-1 Agonists, Exactly?

GLP-1 stands for glucagon-like peptide-1. These drugs mimic a hormone your gut naturally produces. They slow digestion, reduce appetite, and help regulate blood sugar. Originally designed for type 2 diabetes, they became celebrities almost overnight when it turned out they also caused dramatic weight loss.

But here’s what the headlines keep missing. GLP-1 drugs appear to do a lot more than shrink waistlines. Early research points to real benefits for cardiovascular health, liver disease, kidney function, and inflammation. That last one is especially important when you’re talking about HIV.

The HIV Connection Is Bigger Than You Think

People living with HIV face a disproportionate burden of what doctors call “metabolic complications.” That means higher rates of obesity, diabetes, heart disease, and fatty liver disease. Some of this comes from the virus itself. Some comes from decades of antiretroviral therapy, which has kept millions alive but hasn’t come without side effects.

The data presented at CROI 2026 suggests GLP-1 agonists could directly address these complications. Not just by helping people lose weight, but potentially by reducing systemic inflammation — a persistent problem in HIV-positive individuals even when their viral load is undetectable. That’s a huge deal. Chronic inflammation is linked to accelerated aging, cardiovascular events, and neurological decline.

In other words, we might be looking at a drug class that doesn’t just help people look better on the outside, but actually repairs some of the long-term damage HIV and its treatments leave behind.

So What’s the Problem?

Access. Full stop.

In the United States, a monthly supply of semaglutide can run over $1,000 without insurance. In the Global South — where the majority of the world’s HIV-positive population lives — that price is completely fictional. Unattainable. Laughable, in the darkest possible way.

We’ve seen this story before. Antiretrovirals were revolutionary when they first appeared in the 1990s. They were also priced out of reach for most of the world. It took years of activist pressure, generic manufacturing deals, and global health funding to make them accessible. Millions of people died waiting.

The HIV community knows better than anyone what pharmaceutical inequality looks like. And the GLP-1 situation is shaping up the same way.

There are interesting parallels in how big tech navigates access and power dynamics too. Take, for example, the ongoing debate about whether the UK’s NHS should exit its contract with Palantir — a reminder that when powerful tools meet public health, access and accountability have to be front of mind. The same logic applies here.

Generic Manufacturing Is the Only Realistic Path

The good news is that patents on some GLP-1 compounds will eventually expire. Generic versions are already in development in countries like India and China. Semaglutide’s cost of production, according to researchers, is actually quite low. The price isn’t justified by manufacturing complexity. It’s justified by market exclusivity and corporate profit.

Health advocates are pushing hard for voluntary licensing agreements — the same mechanism that unlocked affordable HIV antiretrovirals for low-income countries. It works. It’s worked before. The question is whether pharmaceutical companies will move fast enough, or whether global health bodies will need to apply significant pressure.

Hot Take: The Real Scandal Isn’t the Drug. It’s the System.

Here’s my controversial opinion. GLP-1 drugs are a miracle. Genuinely. The science is extraordinary. But the way we’re allowing these medicines to be distributed — locked behind premium pricing in wealthy nations while the rest of the world watches — is a policy failure, not a market success story.

Right now, investor sentiment in biotech and pharma is being shaped by the same forces driving big bets and big exits elsewhere in the market. When major investors are reshuffling positions across sectors, health innovation gets caught in those currents. The result is that drugs get priced to satisfy Wall Street, not patients.

The average person — whether they live in Lagos, London, or Louisiana — deserves access to medicines that could extend their healthy years. That’s not radical. That’s basic. And right now, the system isn’t delivering it.

What Needs to Happen Next

Researchers at CROI 2026 were clear. The science is promising. The clinical signal is strong. But without parallel investment in access strategies — generic licensing, price negotiations, global health funding — GLP-1 agonists will become another example of medicine that changed everything for some people and nothing for most.

Advocacy organizations, governments, and health funders need to move now. Before the window closes. Before the patent walls get higher.

This is one of those rare moments where the science and the need are perfectly aligned. Whether the political will catches up in time is the only question that matters.